The pharmaceutical industry’s prospects appear bright, thanks to increasing healthcare spending worldwide amid the rising prevalence of chronic and rare diseases and the growing aging population, combined with consistent research and development (R&D) efforts. Moreover, numerous technological advancements are revolutionizing the industry.
Considering the industry’s rosy outlook, investors could consider investing in quality pharmaceutical stocks CytomX Therapeutics, Inc. (CTMX) and Wave Life Sciences Ltd. (WVE). However, struggling Tilray Brands, Inc. (TLRY) is best avoided now.
